368 POSTER Long-term follow-up study of serum tumor markers CEA and CA 15-3 in patients with breast cancer

Lumachi, Franco; Ermani, Mario; Cristofaro, Loretta Di; Basso, Umberto

doi:10.1016/s0748-7983(06)70803-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, BC-mqmsPCR detected 15 out of 17 stage 0 BC cases (88.2%) that were mainly characterized by carcinoma in situ, while only one case was identified by CEA (1/17, 5.9%), and none were detected by CA153 (0%) or CA125 (0%). Because the traditional tumor markers CEA, CA153, and CA125 may only be used in patients with advanced BC, they are not helpful for screening or diagnosis of early BC 41,42 . For example, CA153 concentrations are increased in 10% of patients with stage I disease, 20% with stage II disease, 40% with stage III disease, and 75% with stage IV disease 43,44 , so ER status, PR status, HER2 status, and Ki67 levels (one-Way ANOVA test, two-sided, Dunnett's test for multiple comparisons).…”

Section: Bc-mqmspcr Outperformed Traditional Methods Of Bc Diagnosismentioning

confidence: 99%

A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer

Wang,

Li,

et al. 2023

Nat Commun

View full text Add to dashboard Cite

The immune system can monitor tumor development, and DNA methylation is involved in the body’s immune response to tumors. In this work, we investigate whether DNA methylation alterations in peripheral blood mononuclear cells (PBMCs) could be used as markers for early detection of breast cancer (BC) from the perspective of tumor immune alterations. We identify four BC-specific methylation markers by combining Infinium 850 K BeadChips, pyrosequencing and targeted bisulfite sequencing. Based on the four methylation markers in PBMCs of BC, we develop an efficient and convenient multiplex methylation-specific quantitative PCR assay for the detection of BC and validate its diagnostic performance in a multicenter cohort. This assay was able to distinguish early-stage BC patients from normal controls, with an AUC of 0.940, sensitivity of 93.2%, and specificity of 90.4%. More importantly, this assay outperformed existing clinical diagnostic methods, especially in the detection of early-stage and minimal tumors.

show abstract

Section: Bc-mqmspcr Outperformed Traditional Methods Of Bc Diagnosismentioning

confidence: 99%

A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer

Wang,

Li,

et al. 2023

Nat Commun

View full text Add to dashboard Cite

show abstract

368 POSTER Long-term follow-up study of serum tumor markers CEA and CA 15-3 in patients with breast cancer

Cited by 1 publication

References 0 publications

A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer

A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer

Contact Info

Product

Resources

About